Moderna’s Mpox Vaccine Shows Superior Efficacy in Preclinical Study Compared to Approved Version

Preclinical Study Results:
Moderna's mpox vaccine has demonstrated superior performance in preclinical studies compared to the currently approved version, suggesting it could be a more effective alternative.

Comparison with JYNNEOS:
The study indicates that Moderna's vaccine outperforms JYNNEOS, the FDA-approved vaccine for mpox prevention, in preclinical trials.

Current Vaccination Landscape:
JYNNEOS is a third-generation vaccine based on a live, attenuated orthopoxvirus (Modified Vaccinia Ankara) and is the dominant vaccine used in the U.S. for mpox prevention.

Potential for New Vaccine Options:
The success of Moderna's vaccine in preclinical studies highlights the potential for new, more effective vaccine options to combat mpox.

Ongoing Research:
Other research, such as the development of synthetic MVA vaccines, also shows promise in providing cross-reactive immunity against mpox.